Compare Novo Nordisk A/S (NVO) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Okta, Inc. — how do they compare? Novo Nordisk A/S trades at $45.01 (market cap $198.57B), while Okta, Inc. trades at $172.8 (market cap $30.20B). The key difference: Novo Nordisk A/S is far larger — about 6.6× Okta, Inc.'s market cap, and Novo Nordisk A/S pays a 4.03% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| NVO | OKTA | |
|---|---|---|
Market Cap | $198.57B | $30.20B |
Sector | Health | Technology |
52-Week High | $63.98 | $173.04 |
52-Week Low | $35.29 | $62.93 |
Enterprise Value | $213.37B | $27.95B |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
OKTA trades at $167.60, down 1.76% on the day but up 94% year-to-date, driven by strong earnings beats and AI-driven demand for cybersecurity. The stock is in a bullish technical trend with support at $166 and resistance at $170. Fundamentals show improving profitability, with Q2 2026 EPS of $1.05 beating estimates, revenue growth accelerating to $2.61 billion in 2025, and a net income margin turning positive to 9.63% in 2026 projections. Analyst sentiment remains overwhelmingly positive with a $181.61 consensus target.
The outlook for OKTA is bullish, supported by robust earnings momentum, AI security adoption, and strong institutional backing. Key opportunities include expanding AI-agent security offerings and sustained revenue growth. Risks involve intense competition from CrowdStrike and Microsoft, high valuation multiples, and insider selling activity. The stock's proximity to its 52-week high suggests cautious entry points may be warranted despite positive catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
